Sept. 30 (Bloomberg) -- Pfizer Inc., the world’s largest drugmaker, is ending early-stage development of treatments for a range of illnesses from obesity to heart disease, to focus on more profitable diseases.
Sept. 30 (Bloomberg) -- Pfizer Inc., the world’s largest drugmaker, is ending early-stage development of treatments for a range of illnesses from obesity to heart disease, to focus on more profitable diseases.
